WO2006040643A3 - Formes polymorphes d'efavirenz et processus de leur fabrication - Google Patents

Formes polymorphes d'efavirenz et processus de leur fabrication Download PDF

Info

Publication number
WO2006040643A3
WO2006040643A3 PCT/IB2005/003013 IB2005003013W WO2006040643A3 WO 2006040643 A3 WO2006040643 A3 WO 2006040643A3 IB 2005003013 W IB2005003013 W IB 2005003013W WO 2006040643 A3 WO2006040643 A3 WO 2006040643A3
Authority
WO
WIPO (PCT)
Prior art keywords
efavirenz
polymorphic forms
processes
preparation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/003013
Other languages
English (en)
Other versions
WO2006040643A2 (fr
Inventor
Ramnik Sharma
Kumar Hari Bhushan
Ram Chander Aryan
Nitu Singh
Bhargav Pandya
Yatendra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006040643A2 publication Critical patent/WO2006040643A2/fr
Publication of WO2006040643A3 publication Critical patent/WO2006040643A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouvelles formes polymorphes d'éfavirenz. Les nouvelles formes polymorphes sont désignées comme formes d'éfavirenz a, ß, ?, ?1, ?2, ?, d, N, O et P. La présente invention concerne aussi une forme amorphe d'éfavirenz. L'invention concerne également des processus de leur préparation et de leur utilisation dans des compositions pharmaceutiques visant le traitement de l'infection par VIH-1.
PCT/IB2005/003013 2004-10-11 2005-10-10 Formes polymorphes d'efavirenz et processus de leur fabrication Ceased WO2006040643A2 (fr)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
IN1959/DEL/2004 2004-10-11
IN1959DE2004 2004-10-11
IN2166DE2004 2004-10-29
IN2169DE2004 2004-10-29
IN2165DE2004 2004-10-29
IN2167/DEL/2004 2004-10-29
IN2164DE2004 2004-10-29
IN2166/DEL/2004 2004-10-29
IN2164/DEL/2004 2004-10-29
IN2167DE2004 2004-10-29
IN2165/DEL/2004 2004-10-29
IN2169/DEL/2004 2004-10-29
IN433DE2005 2005-02-28
IN433/DEL/2005 2005-02-28
IN716/DEL/2005 2005-03-31
IN716DE2005 2005-03-31
IN2680DE2005 2005-10-06
IN2680/DEL/2005 2005-10-06

Publications (2)

Publication Number Publication Date
WO2006040643A2 WO2006040643A2 (fr) 2006-04-20
WO2006040643A3 true WO2006040643A3 (fr) 2006-07-06

Family

ID=36035688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/003013 Ceased WO2006040643A2 (fr) 2004-10-11 2005-10-10 Formes polymorphes d'efavirenz et processus de leur fabrication

Country Status (1)

Country Link
WO (1) WO2006040643A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108630A1 (fr) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Formes polymorphes de l'efavirenz
WO2009011567A1 (fr) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Formes cristallines d'efavirenz
JP2010536798A (ja) 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
WO2009087679A2 (fr) * 2007-12-24 2009-07-16 Matrix Laboratories Limited Procédé de préparation de formes polymorphes de (s)-6-chloro-(cyclopropyléthynyl)-1,4-dihydro-4-(trifluorométhyl)-2h-3,1-benzoxazin-2-one
EP2367804B1 (fr) 2008-12-22 2013-11-06 Hetero Research Foundation Procédé pour la préparation d'un polymorphe de l'éfavirenz
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) * 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6673372B1 (en) * 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965729A (en) * 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6673372B1 (en) * 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz

Also Published As

Publication number Publication date
WO2006040643A2 (fr) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2008075376A8 (fr) Formes polymorphes du bortézomibe et leur procédé de préparation
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008049116A3 (fr) Indoles substitués
WO2004071426A3 (fr) Composes destines au traitement d'une infection virale
WO2005070891A3 (fr) Composes et leurs procedes d'utilisation
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2008136865A3 (fr) (s)-n-stéréoisomères d'analogues de 4,5-époxy-morphinanium saturés en 7,8
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2007122581A3 (fr) Compositions et kits utiles dans le traitement de maladies respiratoires
WO2007044950A3 (fr) Formes cristallines de docetaxel et leurs processus de preparation
WO2007075858A3 (fr) Nouvelles formes de bromure de tiotropium et processus de preparation de celles-ci
WO2008088779A3 (fr) Formes solides de 5-azacytidine et procédés de préparation de ces dernières
WO2009062576A8 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2004106322A3 (fr) Polymorphes d'aripiprazole
WO2007041632A3 (fr) Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2007098273A3 (fr) Nouvelles formes cristallines d'armodafinil et leur preparation
WO2005055943A3 (fr) Derives de la vinorelbine
WO2005075467A3 (fr) Formes cristallines de zolmitriptan
SG10201501376XA (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2010061220A3 (fr) Nouveaux procédés et polymorphes purs
WO2007081909A3 (fr) Formes du mésylate de dolasetron et leurs procédés de préparation
WO2009058267A3 (fr) Dérivés de benzomorpholine et procédés d'utilisation
WO2009019662A3 (fr) Compositions à base de métaxolone orale

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05793351

Country of ref document: EP

Kind code of ref document: A2